Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Is Canada ready for therapeutic vaccines?

Barbara Sibbald
CMAJ January 23, 2017 189 (3) E133-E134; DOI: https://doi.org/10.1503/cmaj.109-5370
Barbara Sibbald
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Within five years, the first 16 of an expected onslaught of therapeutic vaccines will be licensed in the United States. Another 140 are in clinical trials. They are mostly aimed at treating cancers (105), but also allergies (13) and other diseases (25). There are even ones for smoking cessation and cocaine abuse. A handful are also being developed by Canadian vaccine companies.

Like all drugs, therapeutic vaccines will go through the usual Health Canada approval process, but less certain is which agency will conduct the expert evidence-based review to determine which therapeutic vaccines should be publicly funded.

“Are we prepared?” asks Robert Van Exan, a Canadian cell biologist who has worked in the vaccine industry for 35 years. “My purpose is to stimulate people to start thinking and talking about this before it hits us.” He spoke about this need at the 2016 Canadian Immunization Conference in Ottawa.

Unlike traditional vaccines, which prevent an infectious disease, therapeutic vaccines provide treatment for a chronic disease or condition. But the moniker vaccine is appropriate because, like preventive vaccines, therapeutic vaccines deliver an antigen. But rather than jumpstarting the immune system to prevent disease, they stimulate the immune system to do other things, explains Van Exan, who now works as a consultant. In the case of cancers, an antigen can stimulate the body’s immune system to attack a tumour.

In Canada, the National Advisory Committee on Immunization (NACI) provides evidence on the use of vaccines in humans to the Public Health Agency of Canada, which gives advice to provincial ministries of health, who make decisions on public coverage. But NACI deals with vaccines for infectious diseases, not things like monoclonal antibody treatment for Crohn disease and other diseases, points out NACI Chair Dr. Ian Gemmill.

Figure

No one has decided who will present evidence on which therapeutic vaccines should be publicly funded.

Image courtesy of Copyright:Liuhsihsiang/iStock

“These don’t come to NACI at all; these and therapeutics are for a very different purpose,” says Gemmill. In addition, NACI currently approves only one or two vaccines a year and doesn’t have the member expertise or the capacity to assess therapeutic vaccines.

So, where does that leave them?

“What we need to do is to have those conversations to see exactly where they lie. You don’t want them to be orphaned,” says Robert Lerch, executive secretary of the National Advisory Committee on Immunization Secretariat, at the Centre for Immunization and Respiratory Infectious Diseases with the Public Health Agency of Canada. “It may turn out that there is more than one category of therapeutics.”

Various partners will be involved in that conversation, adds Lerch. “We’ll be on the list with other groups. Does it make sense that this come to [NACI]? Well no, but if not here, then where?”

The responsibility could fall to the Canadian Agency for Drugs and Technology in Health (CADTH) or the Pan-Canadian Oncology Drug Review (pCODR).

Alexandra Chambers, director of pCODR, which is part of CADTH, says “nothing’s happened yet.”

“Therapeutic vaccines have definitely come up in conversation,” Chambers adds. “But decisions around who will review them haven’t been made.”

She says CADTH will stick to its usual process, waiting for provincial ministries of health to request a review. “Demand [to the ministries] comes from patients, patient groups or industry. The drug plans are pretty savvy; they see what else is happening internationally, they see the pressures on the horizon.”

CADTH might be better positioned than NACI to do evaluations, Van Exan says. “But do they have resources and expertise? What criteria are they using? Are these the right criteria?”

Van Exan is particularly concerned about how long approval might take. “Getting through NACI and government regulation, procurement and into programs … can take a decade. My fear is if we haven’t sorted it out then everything will get delayed and access for doctors to use these new technologies will get delayed and that would be a crying shame.”

“It’s time to get it on the table,” he said.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (3)
CMAJ
Vol. 189, Issue 3
23 Jan 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Is Canada ready for therapeutic vaccines?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Is Canada ready for therapeutic vaccines?
Barbara Sibbald
CMAJ Jan 2017, 189 (3) E133-E134; DOI: 10.1503/cmaj.109-5370

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Is Canada ready for therapeutic vaccines?
Barbara Sibbald
CMAJ Jan 2017, 189 (3) E133-E134; DOI: 10.1503/cmaj.109-5370
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Providing abortions to Americans could land Canadian doctors in legal trouble — without CMPA assistance
  • Troubling rise in suicides linked with common food preservative
  • Weak SARS-CoV-2 vaccine booster campaign resurrects specter of health care hesistancy
Show more News

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire